IQVIA (NYSE:IQV) gapped up before the market opened on Friday . The stock had previously closed at $103.42, but opened at $101.63. IQVIA shares last traded at $101.63, with a volume of 4133907 shares changing hands.
Several equities research analysts recently weighed in on IQV shares. Zacks Investment Research cut IQVIA from a “hold” rating to a “sell” rating in a report on Tuesday, February 20th. Goldman Sachs raised IQVIA from a “neutral” rating to a “buy” rating in a research report on Friday, April 13th. ValuEngine lowered IQVIA from a “buy” rating to a “hold” rating in a research report on Tuesday, April 3rd. Royal Bank of Canada set a $118.00 price target on IQVIA and gave the company a “buy” rating in a research report on Thursday, February 15th. Finally, JPMorgan Chase upped their price target on IQVIA from $115.00 to $120.00 and gave the company an “overweight” rating in a research report on Thursday, February 15th. Seven investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $110.47.
The stock has a market capitalization of $21.05 billion, a PE ratio of 23.31, a P/E/G ratio of 1.70 and a beta of 0.64. The company has a quick ratio of 1.16, a current ratio of 1.16 and a debt-to-equity ratio of 1.22.
IQVIA (NYSE:IQV) last announced its earnings results on Wednesday, May 2nd. The medical research company reported $1.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.27 by $0.07. IQVIA had a return on equity of 13.35% and a net margin of 13.07%. The firm had revenue of $2.56 billion during the quarter, compared to analyst estimates of $2.42 billion. The company’s quarterly revenue was up 34.1% compared to the same quarter last year. equities analysts anticipate that IQVIA will post 5.06 earnings per share for the current year.
In other news, insider James H. Erlinger III sold 10,000 shares of the stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $100.00, for a total value of $1,000,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Michael J. Evanisko sold 816 shares of the stock in a transaction that occurred on Monday, March 5th. The stock was sold at an average price of $100.00, for a total value of $81,600.00. The disclosure for this sale can be found here. Insiders sold a total of 12,527 shares of company stock valued at $1,257,834 in the last three months. Corporate insiders own 6.00% of the company’s stock.
Several large investors have recently made changes to their positions in IQV. Nisa Investment Advisors LLC purchased a new stake in shares of IQVIA in the 4th quarter worth approximately $920,000. Atria Investments LLC purchased a new stake in shares of IQVIA in the 4th quarter worth approximately $218,000. Louisiana State Employees Retirement System purchased a new stake in shares of IQVIA in the 4th quarter worth approximately $862,000. Bank of Montreal Can purchased a new stake in shares of IQVIA in the 4th quarter worth approximately $12,999,000. Finally, National Pension Service purchased a new stake in shares of IQVIA in the 4th quarter worth approximately $14,823,000. 92.43% of the stock is owned by hedge funds and other institutional investors.
IQVIA Company Profile
IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.